Skip to main content
. Author manuscript; available in PMC: 2014 Jan 13.
Published in final edited form as: Cancer. 2012 Apr 17;118(20):4936–4943. doi: 10.1002/cncr.27502

Figure 1.

Figure 1

Cumulative locoregional recurrence rates among hormone receptor-positive subgroups. Pairwise comparison HR+/HER2− vs HR+/HER2+/No Tz p=0.002; HR+/HER2− vs HR+/HER2+/Yes Tz p=0.506. HR = Hormone receptor; HER2 = Human epidermal growth factor receptor 2; Tz = Trastuzumab.